JPH3 Gene: Junctophilin-3 and Its Role in Huntington's Disease-Like 2
A comprehensive biomedical overview of JPH3, its genomic context, expression, mutations, and associated disorders.
Gene Information Card
| Symbol | JPH3 |
|---|---|
| Full Name | junctophilin 3 |
| Gene Type | protein coding |
| Chromosomal Location | 16q24.3 |
| NCBI Gene ID | 57338 ncbi.nlm.nih.gov/gene/57338 |
| Ensembl ID | ENSG00000154188 |
| UniProt ID | Q9UBC5 |
| OMIM ID | 605268 |
| HGNC ID | 14203 |
| Aliases | JP-3, JP3, HDL2, C16orf26 |
Description
The JPH3 gene encodes junctophilin-3, a protein that plays a crucial role in the formation of junctional membrane complexes between the plasma membrane and the endoplasmic/sarcoplasmic reticulum. These complexes are essential for excitation-contraction coupling in muscle cells and for calcium signaling in neurons. JPH3 is primarily expressed in the brain, particularly in the striatum and cortex, and is involved in maintaining intracellular calcium homeostasis. Mutations in JPH3, specifically an expanded CAG/CTG repeat in the 5' region, cause Huntington's disease-like 2 (HDL2), a rare autosomal dominant neurodegenerative disorder with clinical features similar to Huntington's disease.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Huntington's disease-like 2 (HDL2) | Expansion of a CAG/CTG repeat in the 5' untranslated region of JPH3, leading to a toxic gain-of-function at the RNA level and/or altered protein function, resulting in neurodegeneration. | OMIM: 605268; ClinVar: Pathogenic variants; multiple studies (e.g., Holmes et al., 2001; Margolis et al., 2001) |
| Neurodegeneration with brain iron accumulation (NBIA) - possible association | Altered JPH3 expression or function may contribute to iron accumulation and neuronal death, though the exact mechanism is not fully established. | Limited evidence; some case reports and studies suggest a link, but not confirmed in large cohorts. |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain - cortex | 8.2 | Medium |
| Brain - basal ganglia | 7.5 | Medium |
| Brain - cerebellum | 6.1 | Low |
| Heart | 3.4 | Low |
| Skeletal muscle | 2.8 | Low |
| Testis | 1.5 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| SH-SY5Y (neuroblastoma) | 5.3 | Neuronal model, moderate expression |
| U-87 MG (glioblastoma) | 4.1 | Low expression |
| HepG2 (hepatocellular carcinoma) | 0.8 | Very low expression |
| A549 (lung carcinoma) | 0.5 | Not detected |
Data source:Human Protein Atlas(proteinatlas.org)
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| CAG/CTG repeat expansion (normal: 6-28; pathogenic: >40) | Repeat expansion | Rare (prevalence <0.1% in general population) | Toxic RNA gain-of-function; altered protein interactions; neurodegeneration |
| c.1-105CAG repeat (5' UTR) | Repeat expansion | Pathogenic in HDL2 | Disrupts translation and/or RNA processing |
| Missense variants (e.g., p.Arg112Cys) | Missense | Unknown frequency | Potential loss of protein function; not clearly pathogenic |
Mutation functional classification
Loss of Function (LOF)
Loss of JPH3 function may impair calcium signaling and membrane junction formation, but haploinsufficiency is not the primary mechanism for HDL2; complete loss is not observed in patients.
Gain of Function (GOF)
The expanded CAG/CTG repeat produces a toxic RNA that sequesters RNA-binding proteins (e.g., MBNL1), leading to splicing defects and neuronal toxicity. This is the primary pathogenic mechanism.
Dominant Negative (DN)
The mutant RNA or protein may interfere with the function of the normal allele, but evidence for a dominant-negative effect is limited.
View complete mutation data:
Gene Ontology (GO)
Pathways
• Calcium signaling pathway (Reactome: R-HSA-4086398)
• Excitation-contraction coupling (Reactome: R-HSA-5576891)
• Neurodegeneration pathways (KEGG: hsa05016)
Protein Summary
Junctophilin-3 is a 748-amino acid protein with a molecular weight of approximately 85 kDa. It contains a C-terminal transmembrane domain that anchors it to the endoplasmic/sarcoplasmic reticulum membrane, and an N-terminal domain that interacts with the plasma membrane. The protein forms junctional membrane complexes that are critical for the close apposition of the ER/SR and the plasma membrane, facilitating calcium release and signaling. In neurons, JPH3 is involved in calcium homeostasis, synaptic plasticity, and neuronal survival. Mutations in JPH3, particularly the CAG/CTG repeat expansion, lead to a toxic RNA that disrupts RNA processing and contributes to neurodegeneration in HDL2.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| JPH3 Knockout HEK293 Cell Line | EDJ-KQ13883 | Human | 57338 | Details Get a Quote |
| JPH3 Knockout HeLa Cell Line | EDJ-KQ43738 | Human | 57338 | Details Get a Quote |
| JPH3 Knockout A-549 Cell Line | EDJ-KQ65338 | Human | 57338 | Details Get a Quote |
| JPH3 Knockout HCT 116 Cell Line | EDJ-KQ73777 | Human | 57338 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records